PI3K Pathway Activity and Response to First-Line Chemotherapy in Combination with Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer.

2009 ◽  
Author(s):  
P. Vorkas ◽  
S. Agelaki ◽  
N. Poumpouridou ◽  
N. Poumpouridou ◽  
C. Kroupis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Pi3k Pathway ◽  
First Line ◽  
Her2 Positive ◽  
Pathway Activity ◽  
Line Chemotherapy

Incidence of brain metastases after first line chemotherapy in breast cancer patients treated with or without trastuzumab

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10582-10582
Author(s):  
G. Ferretti ◽  
A. Felici ◽  
M. Pino ◽  
P. Carlini ◽  
A. Fabi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Brain Metastases ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
Breast Cancer Patients ◽  
First Line ◽  
Her2 Positive ◽  
Trastuzumab Therapy ◽  
Line Chemotherapy

10582 Background: Brain metastases during trastuzumab therapy have been frequently observed. Only a few studies have compared the risk of brain metastases in patients (pts) treated with or without trastuzumab. Methods: In our hospital, between Jun 2000 and September 2005, we conducted a retrospective study in 72 metastatic breast cancer pts treated with first-line mono-chemotherapy (CT) with paclitaxel or docetaxel or vinorelbine ± Trastuzumab (T). Results: Thirty-five pts with HER2 pos disease were treated with T associated with 1st line CT, while 37 pts (16 with HER2 positive tumor, 21 HER2 negative) were not treated with T (NT). Ten HER2 pos NT pts subsequently received T. The median follow-up was 21 months (range1–129); the median age was 54 (range 32–82); the median treatment duration was 5 months (range 1–29). The incidence of recurrence (R), progressive disease in brain (BR), progression free survival (PFS) after first line CT, and overall survival (OS) were reported below: (see Table) Conclusions: This study showed that, after first line chemotherapy, the use of T did not affect the incidence of BR in HER2 pos metastatic breast cancer pts. On the other hand, Her-2 neg seems to predict ‘per se‘ a lower incidence of cerebral spread of disease. [Table: see text] No significant financial relationships to disclose.

scholarly journals Luminal-like metastatic breast cancer: which is the room of endocrine maintenance therapy after first line chemotherapy?

2015 ◽  
Vol 26 ◽  
pp. vi3
Author(s):  
S. Moroso ◽  
M. Bonotto ◽  
L. Gerratana ◽  
G. Arpino ◽  
C. De Angelis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Maintenance Therapy ◽  
Metastatic Breast ◽  
First Line ◽  
Line Chemotherapy

scholarly journals An Open‐Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First‐Line HER2‐Positive Metastatic Breast Cancer

2013 ◽  
Vol 18 (6) ◽  
pp. 661-666 ◽  
Author(s):  
Francisco J. Esteva ◽  
Sandra X. Franco ◽  
Maura K. Hagan ◽  
Abenaa M. Brewster ◽  
Robert A. Somer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
First Line ◽  
Her2 Positive ◽  
Open Label ◽  
Safety Study

First-line chemotherapy with or without biologic agents for metastatic breast cancer

2010 ◽  
Vol 76 (2) ◽  
pp. 99-111 ◽  
Author(s):  
Claudia Andreetta ◽  
Alessandro M. Minisini ◽  
Manuela Miscoria ◽  
Fabio Puglisi
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Biologic Agents ◽  
First Line ◽  
Line Chemotherapy

Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel inHER2-Positive Metastatic Breast Cancer

2010 ◽  
Vol 28 (6) ◽  
pp. 976-983 ◽  
Author(s):  
Andrew M. Wardley ◽  
Xavier Pivot ◽  
Flavia Morales-Vasquez ◽  
Luis M. Zetina ◽  
Maria de Fátima Dias Gaui ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Response Rate ◽  
Performance Status ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
First Line ◽  
Her2 Positive ◽  
Grade 3

PurposeTo evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer.Patients and MethodsPatients with HER2-positive locally advanced or metastatic breast cancer were randomly assigned to H (8 mg/kg loading; 6 mg/kg every 3 weeks) plus T (75 mg/m2in HTX arm, 100 mg/m2in HT arm, every 3 weeks) with or without X (950 mg/m2twice per day on days 1 to 14 every 3 weeks). The primary end point was overall response rate (ORR).ResultsIn 222 patients, median follow-up was approximately 24 months. ORR was high with both regimens (70.5% with HTX; 72.7% with HT; P = .717); complete response rate was 23.2% with HTX compared with 16.4% with HT. HTX demonstrated significantly longer progression-free survival: median 17.9 months compared with 12.8 months with HT (hazard ratio, 0.72; P = .045), which translates to a gain of around 5 months. Two-year survival probability was 75% with HTX compared with 66% with HT. Febrile neutropenia (27% v 15%) and grade 3/4 neutropenia (77% v 54%) incidences were higher with HT than HTX. Treatment-related grade 3 hand-foot syndrome (17% v < 1%) and grade 3/4 diarrhea (11% v 4%) occurred more commonly with HTX than HT. One case of congestive heart failure occurred in each arm.ConclusionHTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids.

Sign in / Sign up

Export Citation Format

Share Document